Signaling controversy and future therapeutical perspectives of targeting sphingolipid network in cancer immune editing and resistance to tumor necrosis factor- α immunotherapy
Anticancer immune surveillance and immunotherapies trigger activation of cytotoxic cytokine signaling, including tumor necrosis factor- α (TNF-α) and TNF-related apoptosis-inducing ligand (TRAIL) pathways. The ... (Source: Cell Communication and Signaling)
Source: Cell Communication and Signaling - May 2, 2024 Category: Molecular Biology Authors: Olga A. Sukocheva, Margarita E. Neganova, Yulia Aleksandrova, Jack T. Burcher, Elena Chugunova, Ruitai Fan, Edmund Tse, Gautam Sethi, Anupam Bishayee and Junqi Liu Tags: Review Source Type: research
The role of circular RNAs in regulating resistance to cancer immunotherapy: mechanisms and implications
Cell Death & Disease, Published online: 02 May 2024; doi:10.1038/s41419-024-06698-3The role of circular RNAs in regulating resistance to cancer immunotherapy: mechanisms and implications (Source: Cell death and disease)
Source: Cell death and disease - May 2, 2024 Category: Internal Medicine Authors: Yu Ma Ting Wang Xudong Zhang Pinghan Wang Fangyi Long Source Type: research
Neutrophil-activating secretome characterizes palbociclib-induced senescence of breast cancer cells
In this study, we investigate the induction of cellular senescence in breast cancer cells and the subsequent immunomodulatory effects on neutrophils using the CDK4/6 inhibitor palbociclib, which is approved for the treatment of breast cancer and is under intense investigation for additional malignancies. Our research demonstrates that palbociclib induces a reversible form of senescence endowed with an inflammatory secretome capable of recruiting and activating neutrophils, in part through the action of interleukin-8 and acute-phase serum amyloid A1. The activation of neutrophils is accompanied by the release of neutrophil ...
Source: Cancer Immunology, Immunotherapy - May 2, 2024 Category: Cancer & Oncology Source Type: research
Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms
ConclusionsLNEN subtypes have characteristic and widely divergent VISTA, OX40L, GITR, and TIM3 protein expressions. By shedding light on the different expression patterns of these immunotherapy targets, the current multicenter study provides support for the future implementation of novel immunotherapeutic approaches. (Source: Cancer Immunology, Immunotherapy)
Source: Cancer Immunology, Immunotherapy - May 2, 2024 Category: Cancer & Oncology Source Type: research
Extracellular matrix stiffness and tumor-associated macrophage polarization: new fields affecting immune exclusion
AbstractIn the malignant progression of tumors, there is deposition and cross-linking of collagen, as well as an increase in hyaluronic acid content, which can lead to an increase in extracellular matrix stiffness. Recent research evidence have shown that the extracellular matrix plays an important role in angiogenesis, cell proliferation, migration, immunosuppression, apoptosis, metabolism, and resistance to chemotherapeutic by the alterations toward both secretion and degradation. The clinical importance of tumor-associated macrophage is increasingly recognized, and macrophage polarization plays a central role in a serie...
Source: Cancer Immunology, Immunotherapy - May 2, 2024 Category: Cancer & Oncology Source Type: research
New genetic insights into immunotherapy outcomes in gastric cancer via single-cell RNA sequencing and random forest model
ConclusionThe random forest model, based on scRNA-seq, shows high predictive value for survival and immunotherapy sensitivity in gastric cancer patients. This study underscores the potential of METTL1 as a biomarker in enhancing the efficacy of gastric cancer immunotherapy. (Source: Cancer Immunology, Immunotherapy)
Source: Cancer Immunology, Immunotherapy - May 2, 2024 Category: Cancer & Oncology Source Type: research
Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing
Chimeric antigen receptor (CAR) designs that incorporate pharmacologic control are desirable; however, designs suitable for clinical translation are needed. We designed a fully human, rapamycin-regulated drug product for targeting CD33+ tumors called dimerizaing agent–regulated immunoreceptor complex (DARIC33). T cell products demonstrated target-specific and rapamycin-dependent cytokine release, transcriptional responses, cytotoxicity, and in vivo antileukemic activity in the presence of as little as 1 nM rapamycin. Rapamycin withdrawal paused DARIC33-stimulated T cell effector functions, which were restored following r...
Source: Journal of Clinical Investigation - May 1, 2024 Category: Biomedical Science Authors: Jacob Appelbaum, April E. Price, Kaori Oda, Joy Zhang, Wai-Hang Leung, Giacomo Tampella, Dong Xia, Pauline P.L. So, Sarah K. Hilton, Claudya Evandy, Semanti Sarkar, Unja Martin, Anne-Rachel Krostag, Marissa Leonardi, Daniel E. Zak, Rachael Logan, Paula Le Source Type: research
Neutrophils in pancreatic ductal adenocarcinoma: bridging preclinical insights to clinical prospects for improved therapeutic strategies
Expert Rev Clin Immunol. 2024 May 1. doi: 10.1080/1744666X.2024.2348605. Online ahead of print.ABSTRACTINTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy characterized by a dismal five-year survival rate of less than 10%. Neutrophils are key components of the innate immune system, playing a pivotal role in the PDAC immune microenvironment.AREAS COVERED: This review provides a comprehensive survey of the pivotal involvement of neutrophils in the tumorigenesis and progression of PDAC. Furthermore, it synthesizes preclinical and clinical explorations aimed at targeting neutrophils within t...
Source: Expert Review of Clinical Immunology - May 1, 2024 Category: Allergy & Immunology Authors: Yi Jin Eric S Christenson Lei Zheng Keyu Li Source Type: research
Erdafitinib and checkpoint inhibitors for first-line and second-line immunotherapy of hepatic, gastrointestinal, and urinary bladder carcinomas: Recent concept
World J Hepatol. 2024 Apr 27;16(4):490-493. doi: 10.4254/wjh.v16.i4.490.ABSTRACTCancer immunotherapy is administered for first-line, second-line, neoadjuvant, or adjuvant treatment of advanced, metastatic, and recurrent cancer in the liver, gastrointestinal tract, and genitourinary tract, and other solid tumors. Erdafitinib is a fibroblast growth factor receptor (FGFR) inhibitor, and it is an adenosine triphosphate competitive inhibitor of FGFR1, FGFR2, FGFR3, and FGFR4. Immune checkpoint inhibitors are monoclonal antibodies that block programmed cell death protein 1 (PD-1) and its ligand that exert intrinsic antitumor mec...
Source: World Journal of Hepatology - May 1, 2024 Category: Gastroenterology Authors: Mohamed Wishahi Source Type: research
Mechanisms of tumor immunosuppressive microenvironment formation in esophageal cancer
World J Gastroenterol. 2024 Apr 28;30(16):2195-2208. doi: 10.3748/wjg.v30.i16.2195.ABSTRACTAs a highly invasive malignancy, esophageal cancer (EC) is a global health issue, and was the eighth most prevalent cancer and the sixth leading cause of cancer-related death worldwide in 2020. Due to its highly immunogenic nature, emer-ging immunotherapy approaches, such as immune checkpoint blockade, have demonstrated promising efficacy in treating EC; however, certain limitations and challenges still exist. In addition, tumors may exhibit primary or acquired resistance to immunotherapy in the tumor immune microenvironment (TIME); ...
Source: World Journal of Gastroenterology - May 1, 2024 Category: Gastroenterology Authors: Xiao-Jun Zhang Yan Yu He-Ping Zhao Lei Guo Kun Dai Jing Lv Source Type: research
Mast Cell-Neutrophil Communication Regulates Allergic Diseases
Yakugaku Zasshi. 2024;144(5):483-488. doi: 10.1248/yakushi.23-00154-2.ABSTRACTAllergic diseases (e.g., food allergies) are a growing problem, with increasing numbers of individuals experiencing them worldwide. Congruently, the adverse reactions (e.g., anaphylaxis) associated with the administration of vaccines against emerging infectious diseases such as coronavirus disease 2019 (COVID-19) have become a familiar problem. Allergic diseases, which have a wide variety of symptoms, are difficult to prevent or cure; treatment is currently limited to therapeutic drugs or allergen immunotherapy. Therefore, elucidating new allergi...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - May 1, 2024 Category: Drugs & Pharmacology Authors: Ryo Suzuki Source Type: research
Mechanisms of tumor immunosuppressive microenvironment formation in esophageal cancer
World J Gastroenterol. 2024 Apr 28;30(16):2195-2208. doi: 10.3748/wjg.v30.i16.2195.ABSTRACTAs a highly invasive malignancy, esophageal cancer (EC) is a global health issue, and was the eighth most prevalent cancer and the sixth leading cause of cancer-related death worldwide in 2020. Due to its highly immunogenic nature, emer-ging immunotherapy approaches, such as immune checkpoint blockade, have demonstrated promising efficacy in treating EC; however, certain limitations and challenges still exist. In addition, tumors may exhibit primary or acquired resistance to immunotherapy in the tumor immune microenvironment (TIME); ...
Source: World Journal of Gastroenterology : WJG - May 1, 2024 Category: Gastroenterology Authors: Xiao-Jun Zhang Yan Yu He-Ping Zhao Lei Guo Kun Dai Jing Lv Source Type: research
Neutrophils in pancreatic ductal adenocarcinoma: bridging preclinical insights to clinical prospects for improved therapeutic strategies
Expert Rev Clin Immunol. 2024 May 1. doi: 10.1080/1744666X.2024.2348605. Online ahead of print.ABSTRACTINTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy characterized by a dismal five-year survival rate of less than 10%. Neutrophils are key components of the innate immune system, playing a pivotal role in the PDAC immune microenvironment.AREAS COVERED: This review provides a comprehensive survey of the pivotal involvement of neutrophils in the tumorigenesis and progression of PDAC. Furthermore, it synthesizes preclinical and clinical explorations aimed at targeting neutrophils within t...
Source: Expert Review of Clinical Immunology - May 1, 2024 Category: Allergy & Immunology Authors: Yi Jin Eric S Christenson Lei Zheng Keyu Li Source Type: research
Erdafitinib and checkpoint inhibitors for first-line and second-line immunotherapy of hepatic, gastrointestinal, and urinary bladder carcinomas: Recent concept
World J Hepatol. 2024 Apr 27;16(4):490-493. doi: 10.4254/wjh.v16.i4.490.ABSTRACTCancer immunotherapy is administered for first-line, second-line, neoadjuvant, or adjuvant treatment of advanced, metastatic, and recurrent cancer in the liver, gastrointestinal tract, and genitourinary tract, and other solid tumors. Erdafitinib is a fibroblast growth factor receptor (FGFR) inhibitor, and it is an adenosine triphosphate competitive inhibitor of FGFR1, FGFR2, FGFR3, and FGFR4. Immune checkpoint inhibitors are monoclonal antibodies that block programmed cell death protein 1 (PD-1) and its ligand that exert intrinsic antitumor mec...
Source: World Journal of Hepatology - May 1, 2024 Category: Gastroenterology Authors: Mohamed Wishahi Source Type: research
Serum interleukin-10 and alpha-fetoprotein: A combined diagnostic approach for hepatocellular carcinoma in Egyptians with HCV
CONCLUSION: the reliability of AFP as a major HCC marker was poor. However, IL-10 levels are a novel biomarker for the degree of HCC inflammation, considering IL-10's potential role in HCV-HCC development. We suggest combining AFP with IL-10 to improve the diagnostic and prognostic value of HCC considerably. Future research on these biomarkers should prioritize their clinical validity, prognostic usefulness, and compatibility with other therapeutic approaches as immunotherapy.PMID:38692084 | DOI:10.1016/j.prp.2024.155327 (Source: Pathology, Research and Practice)
Source: Pathology, Research and Practice - May 1, 2024 Category: Pathology Authors: Mostafa A Sharafeldin Reda A Suef Adel A Mousa Dina H Ziadah Mohamed M S Farag Source Type: research
